.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

CAR-T Cell Therapy Use in B-Cell Malignancies

EP. 1: The Status of CAR T in Hematologic Malignancies

January 9th 2018

EP. 2: Practicality of CAR T Therapy

January 9th 2018

EP. 3: Managing CAR T-Cell Therapy Toxicity

January 9th 2018

EP. 4: Mechanisms of Resistance for CAR T Therapy

January 9th 2018

EP. 5: The Promise of CAR T-Cell Therapy for ALL

January 9th 2018

EP. 6: Tisagenlecleucel for Relapsed/Refractory ALL

January 9th 2018

EP. 7: Clinical Data Behind CAR T-Cell Therapies in ALL

January 9th 2018

EP. 8: Need for Salvage Therapies in R/R NHL

January 9th 2018

EP. 9: FDA Approval for Axi-Cel in NHL

January 9th 2018

EP. 10: Clinical Data for Axi-Cel in Lymphoma

January 9th 2018

EP. 11: Axi-Cel and Future of CAR T-Cell Therapy in Lymphoma

January 9th 2018

EP. 12: JCAR017 for B-Cell NHL

January 9th 2018

EP. 13: The Use of CTL019 in Lymphoma

January 9th 2018

EP. 14: Allogeneic CAR T-Cell Approaches for NHL

January 9th 2018

EP. 15: BCMA-Targeted CAR T-Cell Therapy for Myeloma

January 9th 2018

EP. 16: Potential for CAR T-Cell Therapy for R/R AML

January 9th 2018

EP. 17: Evaluating CAR T-Cell Therapy Use

January 9th 2018

EP. 18: Cost Effectiveness and Future of CAR T Therapy

January 9th 2018